Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis

Summary

The fibrinolytic system was investigated in 120 patients with spontaneous or recurrent deep vein thrombosis (DVT) without any known organic disease able to explain by itself the occurrence of a thrombosis and without any known defect of antithrombin III, Heparin Cofactor II, Protein C, or Protein S. The assays included: Euglobulin fibrinolytic activity (EFA), tissue-type plasminogen activator related antigen (t-PA-Ag) and plasminogen activator inhibitor activity (PA inhibitor), which were measured before and after 10 min of venous occlusion (V. O.). On the basis of the results, the patients could be classified in 3 groups:good responders with an at least two-fold increase of EFA after venous occlusion (n = 76), poor responders with a lesser increase of EFA due to deficient release of t-PA (n = 12), and poor responders with a normal t-PA release but an increased level of PA-Inhibitor (n = 32).

The poor responders due to deficient t-PA release (10% of total) had a higher incidence of recurrence of deep vein thrombosis, than the other groups (p <0.01). An overall correlation was found between the level of PA-Inhibitor activity and the triglyceride level (r = 0.40, p <0.01), suggesting that these elevations may be due to a common cause, at least in some of the patients.

It is concluded that a poor fibrinolytic response to venous occlusion occurs in 35 percent of DVT patients. Poor responders however fall into two categories, one fourth with deficient t-PA release who have a high risk for recurrent venous thrombosis, and three fourth with increased PA-Inhibitor levels which may be associated with underlying diseases also causing hypertriglyceridemia. Further elucidation of the correlation between recurrent venous thrombosis and deficient fibrinolysis is expected to result in more specific and adequate treatment and prevention of DVT.

Keywords

Tissue type plasminogen activator (t-PA) - PA inhibitor - Deep venous thrombosis - Fibrinolysis

• References

• 1 Brommer E JP, Verheijen JH, Chang G TG, Rijken DC. Masking of fibrinolytic response to stimulation by an inhibitor of tissue-type plasminogen activator in plasma. Thromb Haemostas 1984; 52: 154-156
• 2 Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Brit Med J 1985; 290: 1453-1455
• 3 Wiman B, Ljungberg B, Chmielewska J, Urden G, Blombiick M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105: 265-270
• 4 Stalder M, Hauert J, Kruithof E KO, Bachmann F. Release of vascular plasminogen activator (v-PA) after venous stasis: Electrophoreticzymographic analysis of free and complexed v-PA. Brit J Haematol 1985; 61: 169-176
• 5 Kluft C, Brakman P, Veldhuyzen-Stolk EC. Screening of fibrinolytic activity in plasma euglobulin fraction on the fibrin plate. In Progress in chemical fibrinolysis and thrombosis. Davidson JF, Samama MM, Desnoyers PC. (Eds). vol II. pp 57-65 Raven Press; New York: 1976
• 6 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas 1985; 54: 684-687
• 7 Juhan-Vague I, Moerman B, De Cock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-530
• 8 Bucolo G, David M. Quantitative determination of serum triglycerides by use of enzymes. Clin Chem 1973; 19: 475-482
• 9 Rijken DC, Juhan-Vague I, Collen D. Complexes between extrinsic plasminogen activator and proteinase inhibitors in human plasma identified with an immunoradiometric assay. J Lab Clin Med 1983; 101: 285-294
• 10 Juhan-Vague I, Rijken DC, De Cock F, Mendez C, Collen D. Extrinsic plasminogen activator levels in clinical plasma samples. In Progress in fibrinolysis. Davidson JF, Bachmann F, Bouvier CA, Kruithof E KO. (Eds). vol VI, pp 65-72 Churchill Livingstone; Edinburgh - London - Melbourne - New York: 1983
• 11 Ahmad M, Saku K, Glas-Greenwalt P, Kashyap ML. Inhibitor and activator of plasminogen in patients with hyperlipoproteinemias. Thromb Haemostas 1985; 54: 266 (Abstr)
• 12 Hamsten A, Wiman B, De Faire U, Blombiick M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. New Engl J Med 1985; 313: 1557-1563
• 13 Vague Ph, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, PA-Inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250-253
• 14 Juhan-Vague I, Aillaud MF, De Cock F, Philip-Joet C, Arnaud C, Serradimigni A, Collen D. The fast-acting inhibitor of tissue-type plasminogen activator is an acute phase reactant protein. In Progress in fibrinolysis. Davidson JF, Donati MB, Coccheri S. (Eds). vol VII, pp 146-149 Churchill Livingstone; Edinburg - London - Melbourne - New York: 1985
• 15 Aillaud MF, Juhan-Vague I, Alessi MC, Marecal M, Vinson MF, Arnaud C, Vague Ph, Collen D. Increased level of plasminogen activator inhibitor (PA-I) in the post-operative period. No relationship with increased cortisol. Thromb Haemostas 1985; 54: 466-468
• 16 Kluft C, Verheijen JH, Jie A FH, Rijken DC, Preston FE, Sue-Ling HM, Jespersen J, Aasen AO. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45: 605-610